Secondly, on how good the intake ability of the individual is, considering stomach and gut health, toxic strain and/or increased need
Retatrutide targets GLP1 + GIP + glucagon, so some commentators have started calling it GLP3 to suggest a thirdgeneration medication. How Retatrutide Works: Triple Agonist Mechanism Retatrutide is being developed as a onceweekly injectable that activates GLP1, GIP, and glucagon receptors at the same time to influence appetite, blood sugar, and energy expenditure. GLP1 receptor activation Reduces appetite and food intake
easily crosses the blood-brain barrier
its relevance to retatrutide specifically is not yet established A history of pancreatitis or significant gastrointestinal disease Gallbladder disease , including a history of gallstones or cholecystitis Diabetes mellitus , particularly if managed with insulin or sulphonylureas, due to hypoglycaemia risk Cardiovascular disease , including arrhythmias or recent cardiac events Renal or hepatic impairment , which may affect tolerability and increase the risk of dehydration-related complications Pregnancy or breastfeeding no safety data exist for retatrutide in these groups Use of oral medicines where absorption may be affected by delayed gastric emptying , such as levothyroxine or combined oral contraceptives Seek urgent medical attention if you experience severe or persistent nausea or vomiting, persistent abdominal pain (which may indicate pancreatitis or gallbladder disease), signs of an allergic reaction (rash, swelling, difficulty breathing), chest pain, palpitations, or signs of dehydration
